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Abstract
Background and Purpose—It is hypothesized that tPA rescues brain tissue by improving
perfusion. In this study, we aimed to examine acute regional perfusion changes and how they
influence infarction and clinical outcome.
Methods—Three sequential MR scans were performed in 15 tPA-treated patients within 3.5
(tp1), at 6 hours (tp2), and at 1 month (tp3) after stroke onset. “Hypoperfusion” was defined if
MTT prolongation was > a threshold (four thresholds: 3, 4, 5, and 6 seconds). Four ROIs were
classified: 1) “Reperfusion” – hypoperfused at tp1, normal at tp2; (2) “Non-reperfusion” –
hypoperfused at tp1 and tp2; (3) “Normal perfusion” – normal at tp1 and tp2; and (4) “New
hypoperfusion” – normal at tp1 and hypoperfused at tp2. Risk of infarction was calculated within
each ROI. Associations between tissue perfusion changes and clinical variables were evaluated
using step-wise multiple linear regressions. Moreover, the association between NIHSS changes
and perfusion alterations was assessed using linear mixed effect models.
Results—Regardless of the MTT threshold chosen, the risk of infarction in non-reperfused
regions (40–68%, thresholds 3–6 seconds) was higher than reperfused regions (9–30%, P< 0.05),
and it was higher in new hypoperfusion regions (9–33%) than normal perfusion regions (3–4%, P
< 0.05). Volume of new hypoperfusion was significantly associated with onset-to-treatment time
and initial hypoperfused volume. Overall relative reperfusion was significantly associated with
NIHSS improvement.
Conclusion—Early tissue perfusion changes influenced final tissue fate. The development of
new hypoperfusion may result from delay in tPA and a large initial lesion.
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Introduction
Restoration of blood flow to ischemic regions in a timely manner enhances clinical
improvement 1, 2. Moreover, tissue reperfusion is thought to be the leading mechanism
underlying the efficacy of intravenous (IV) recombinant tissue plasminogen activator
(tPA) 3–9. If reperfusion occurs early, it may promote survival in vulnerable tissue that
would otherwise progress to infarction without reperfusion 9, 10. Despite the importance of
time-to-reperfusion on clinical outcome after stroke, few studies have critically examined
tissue perfusion changes within the first several hours after stroke onset.
While recanalization or reperfusion in acute stroke may occur either by medical intervention
or spontaneously up to several days after stroke onset, clinical benefit from reperfusion-
promoting therapies has only been found if it is given within six hours from symptom
onset 2, 9, 11. Thus, in order to understand clinically relevant reperfusion, studies should be
conducted within this six hour window. The EPITHET9 and DEFUSE10 studies examined
diffusion-perfusion mismatch at two time points during acute ischemic stroke. The two
studies differed with respect to the time for assessing reperfusion with a median of 9 hours
for DEFUSE and a median of 3 days for EPITHET. Given the delayed assessment of
reperfusion beyond the clinically relevant reperfusion time-window, these studies may have
under-estimated the impact of early reperfusion. In this study, we hypothesize that there are
substantial temporal and spatial heterogeneities in tissue reperfusion within 6 hours from
stroke onset and the extent to which tissue reperfusion may depend on baseline clinical
variables and initial lesion volumes. Voxel-based analysis, utilizing a six hour assessment
for reperfusion in a cohort of hyper-acute tPA-treated ischemic stroke patients, we measured
the effects of perfusion alterations on risk of infarction at one month. Moreover, associations
between perfusion alterations and clinical variables such as onset-to-treatment time (OTT)
and change in the National Institutes of Health Stroke Scale (NIHSS) were evaluated.
Methods
Patients and Inclusion Criteria
All protocols were approved by the Institutional Review Board. Consecutive patients within
three hours of stroke onset were considered for enrollment based on the following pre-
specified inclusion criteria: clinically-suspected cortical acute ischemic stroke; age 18 years
or older; NIHSS ≥ 5; could be imaged immediately after tPA bolus (within ~3.5 hours of
stroke onset); and patient or patient’s next of kin capable of informed consent. Exclusion
criteria included bilateral strokes or any acute endovascular or surgical intervention. In this
study, only tPA treated patients were included for subsequent data analysis. Patients were
given IV tPA according to NINDS tPA trial protocol 4. The study imposed no delay in time-
to-tPA-treatment and no deviation from standard monitoring practices. The NIHSS was
obtained on admission and at all imaging time points.
Magnetic Resonance Imaging Protocol
Patients were scanned with MRI at three time points: within 3.5 hours (tp1), at 6 hours (tp2),
and at 1 month (tp3) after stroke onset. The tp1 scan was performed as soon as possible,
usually while tPA was infusing. MR images were acquired on a 3T Siemens whole body
Trio system (Siemens Medical Systems, Erlangen, Germany) with a circular polarized head
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coil. The imaging protocol included diffusion-weighted images, T2-weighted FLAIR images
(TR/TE = 10000/115 ms; inversion time = 2500 ms; matrix=512 × 416; 20 slices, slice
thickness (TH) =5 mm), and dynamic susceptibility contrast (DSC) perfusion imaging (a
T2*-weighted gradient echo EPI sequence; TR/TE=1500/43 ms; 14 slices, TH=5 mm, zero
interslice gap; matrix=128×128). The DSC sequence was repeated 50 times with contrast
injection on the 5th measure using Gadolinium diethylenetriamine penta-acetic acid 0.1
mmol/kg at a rate of 5 ml/s with a power injector, followed by a 15 ml bolus of saline. MR
angiography was not performed.
Data analysis
For DSC perfusion imaging, we followed established procedures 12 for the estimation of
mean transit time (MTT) by using the ratio between cerebral blood volume (CBV) and
cerebral blood flow (CBF) as MTT=CBV/CBF. Voxels within the middle cerebral artery
(MCA) of the contralateral hemisphere were manually chosen to obtain an arterial input
function.
Six parameter rigid image registration was performed to align DSC and FLAIR images
across all scans for each patient using a well established registration package FSL 3.2
(FMRIB, Oxford, UK)13. Accuracy of image registration was evaluated manually by
checking multiple structural landmarks, such as the ventricle and brain boundaries, in all
registered images and their corresponding template image for each patient.
MTT was chosen to define perfusion status because MTT is uniform across gray and white
matter (unlike CBF or CBV), allowing for use of a single threshold across both gray and
white matter 14–16. MTT prolongation was computed by subtracting the mean MTT value
for the contralateral hemisphere from the MTT value in the ischemic hemisphere for each
voxel. A voxel was defined as “hypoperfused” if MTT prolongation ≥ a pre-defined
threshold or normal otherwise. Because the abnormal lesion volume varies depending on the
MTT threshold chosen 17–20, four MTT prolongation thresholds (3, 4, 5, and 6 seconds)
were tested to determine if results were consistent across a range of putative thresholds.
Four different categories of regions were defined based on the initial perfusion status at tp1
and its subsequent change at tp2. For regions with initial abnormal perfusion on tp1, two
different perfusion patterns were defined: (1) “reperfusion”, hypoperfused at tp1, normal at
tp2 and (2) “non-reperfusion,” hypoperfused at tp1 and tp2. Moreover, for initially normal
perfused regions at tp1, two different perfusion patterns were defined: (3) “normal
perfusion,” normal at both tp1 and tp2 (4) and “new hypoperfusion,” normal at tp1 and
abnormal at tp2 (Table 1). Isolated regions smaller than 1 ml were removed from the
analysis to minimize inclusion of regions of misregistration or noise-induced variations.
The absolute volume of the hypoperfused region at tp1 was defined as Vhypo_tp1. The
absolute volumes of reperfusion (Vreperf) and new hypoperfusion (Vnewhypo) from each
patient were obtained. Subsequently, the absolute net change of reperfused volume
(Vnetchange) was calculated as Vreperf – Vnewhypo with a positive Vnetchange indicating a net
improvement in perfusion at tp2. Relative volumes of reperfusion (%Vreperf), new
hypoperfusion (% Vnewhypo), and net change (%Vnetchange) were computed as Vreperf/
Vhypo_tp1, Vnewhypo / Vhypo_tp1, and Vnetchange/ Vhypo_tp1, respectively.
Final lesions were outlined independently by a neuroradiologist (R.P.) and a stroke
neurologist (A.F.) as hyperintense regions on the tp3 FLAIR images. An evaluation of the
inter-operator agreement was performed with a similarity index (SI) using the Dice
coefficient 21, computed as 2 |A ∩ B | / (|A|+|B|), where A and B are the final infarct
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outlined by each operator, respectively. The SI ranges from 0 to1, with 0 and 1
corresponding to no and perfect agreement, respectively.
Final lesions were mapped back to the tp1 and tp2 MTT maps. To evaluate the fate of these
regions, risks of infarction in the regions of reperfusion, non-reperfusion, new
hypoperfusion, and normal perfusion were computed as the ratio of the number of infarcted
voxels to the total number of voxels for a specific region.
Statistical Analysis
Variance across MTT Thresholds and Infarction Risk—To evaluate whether
varying the MTT threshold would affect the volumes of different perfusion regions, non-
parametric repeated measures ANOVA (Friedman test) was utilized. Moreover, to assess
whether MTT values differed between reperfused and non-reperfused regions at tp1 and
between new hypoperfused regions and normal perfused regions at tp1, non-parametric
unpaired comparison (Mann-Whitney Test) were performed. The risk of infarction within
the regions of reperfusion and non-reperfusion were compared, as well as between normal
perfusion and new hypoperfusion, using non-parametric unpaired comparisons (Mann-
Whitney Test).
Association between change of tissue perfusion and baseline clinical
variables—Baseline clinical variables, including OTT, age, systolic and diastolic blood
pressure, and glucose level were obtained from all patients. To examine the association
between the clinical variables and the absolute or relative volumes of reperfusion, new
hypoperfusion, and net perfusion change, a stepwise multiple linear regression analysis was
performed (SAS 9.2, SAS Institute Inc., Cary, NC, USA). Stepwise linear regression was
utilized to select the independent variables that might yield a potential association (F
statistic, p<0.15). In the final linear regression model, a P value < 0.05 was considered
significant.
Association between clinical outcome and change of tissue perfusion—Four
linear mixed effect models (SAS 9.2) were used to examine the association between
temporal NIHSS change and Vreperf, Vnetchange , %Vreperf, and %Vnetchange, respectively.
Overall change in NIHSS (from scores obtained at admission, tp1, tp2, and tp3, constructed
as a vector) was modeled as the dependent variable, while baseline clinical variables, and
each of the Vreperf, Vnetchange , %Vreperf, and %Vnetchange were considered as fixed effects in
each mixed effect model. Within-subject correlations of repeated NIHSS measurements at
various times were accounted for.
Results
Fifteen ischemic stroke patients treated with IV tPA (1.8±0.5 hours from symptom onset)
were imaged with MRI at 2.7 ± 0.7 hours (tp1) and 6.4± 0.5 hours (tp2) after onset. Thirteen
patients had a one month follow-up scan (tp3) to determine the final infarct. The tp1 scan
was performed while tPA was still infusing in 12 patients and begun shortly after the
completion of tPA in the remaining three patients. The time interval between the end of tPA
infusion and the tp2 scan was 3.6 ± 0.7 hours. Patient demographics including baseline
clinical information are shown in Table 2. All patients had middle cerebral artery (MCA)
strokes with mean NIHSS equal to 14.
Background susceptibility effects manifested as signal void and geometric distortion were
occasionally observed in the anterior portion of brain in the DSC images, but did not
localize within the ischemic lesion. Moreover, unlike the non-linear transformation, the rigid
image registration was insensitive to these local signal changes. The co-registered images
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were well-aligned with the template images yielding inaccuracies less than three voxels in
any direction.
Perfusion Alterations between tp1 and tp2
Changes in perfusion status between tp1 and tp2 were studied by examining regions of
reperfusion, non-reperfusion, normal perfusion, and new hypoperfusion (Table 1) using four
MTT thresholds (3, 4, 5, and 6 seconds). Several MTT thresholds were utilized to evaluate
whether the major findings depend on specific threshold. As anticipated, the initial ischemic
volume decreased significantly with each increase in MTT threshold (P<0.001). Across
different MTT thresholds, several findings were consistently detected (Table 3): (1)
concurrent existence of reperfused and new hypoperfused regions were observed; (2)
absolute volumes of new hypoperfusion and net change in perfusion did not differ across
thresholds (P=0.18 and P=0.28, Friedman tests); (3) tp1 MTT values in non-reperfused
regions were higher than tp1 MTT values in reperfused regions (P < 0.001), suggesting that
regions with severe ischemia were less likely to reperfuse after tPA; and (4) tp1 MTT values
in the new hypoperfused regions were higher than tp1 MTT values in normal perfused
regions (P < 0.05). The constancy of the above points regardless of MTT threshold is
illustrated in the scatter plots (Fig 1), which show the absolute and relative volumes of
reperfusion, new hypoperfusion, and net change obtained using the four MTT thresholds.
MTT maps from two representative patients are shown in Fig 2. For patient #1 (upper
panel), the majority of the initially hypoperfused brain region (Fig. 2a) reperfused at tp2
(Fig. 2c/d, green), while a small region had no reperfusion (Fig. 2b, yellow). A small region
of new hypoperfusion (or delayed hypoperfusion) was observed at tp2 (Fig. 2c/d, red). In
contrast, patient #2 (lower panel) showed only a small region of reperfusion at tp2 (Fig. 2g/
h, green), but had a large new hypoperfused region at tp2 (Fig. 2g/h, red). For all patients,
the areas of new hypoperfusion were found within the affected MCA ischemic territory and
were not seen within other vascular distributions such as anterior or posterior cerebral artery
territories.
Risk of infarction
The inter-operator SI for manually-defined final lesion areas was 0.87±0.1, suggesting good
agreement between the operators. One set of ROIs (A.F.) was utilized for final infarction
analysis. On tp2 or tp3 imaging, there were no new areas of restricted diffusion or infarction
outside of the initially affected territory. For brain tissue that was hypoperfused at tp1, the
risk of infarction in non-reperfused regions was higher than the reperfused regions (P < 0.05,
Mann-Whitney Test). For tissue that was normally perfused at tp1, the risk of infarction in
the new hypoperfused regions was higher than the normal perfusion regions (P < 0.05,
Mann-Whitney Test) (Table 3).
Association between tissue perfusion changes and OTT and initial hypoperfusion
Although no association was found between the absolute volume of reperfusion (Vreperf) and
other baseline variables including OTT or Vhypo_tp1 (Fig. 3a), a negative association was
found between the relative volume of reperfusion (%Vreperf) and the volume of
hypoperfusion at tp1 (Vhypo_tp1) (r=−0.67, P < 0.01, Fig. 3b). The volume of new
hypoperfusion (Vnewhypo) correlated positively with the tp1 volume of hypoperfusion
(Vhypo_tp1) and OTT (r=0.76, P < 0.05, Fig. 3c). Taken together, these findings suggest that
large strokes are less likely to reperfuse and more likely to develop new regions of
hypoperfusion. Moreover, a shorter OTT may minimize the development of new
hypoperfusion. In agreement with the above results, the relative volume of new
hypoperfusion (%Vnewhypo) correlated positively (r=0.57, P < 0.05, Fig. 3d) and volume of
net change in perfusion (Vnetchange) correlated negatively with OTT (r=−0.59, P < 0.01, Fig.
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3e). Additionally, both volume of hypoperfusion at tp1 (Vhypo_tp1) and OTT correlated
negatively with relative volume of net change (%Vnetchange) (r=−0.82, P <0.05, Fig. 3f),
suggesting that a large region of early ischemia and a prolonged OTT may result in less
overall improvement in perfusion status.
Association between tissue perfusion changes and clinical outcomes
Across the study cohort, NIHSS decreased from admission to tp3 (P <0.0001). When
comparing the four different MTT thresholds, an interesting pattern emerged. MTT
prolongation thresholds of 3 and 4 seconds showed an association between temporal NIHSS
change and %Vreperf (P<0.05, threshold =3 sec, p=0.066 threshold=4 sec). In addition, a
similar association was found between temporal NIHSS and %Vnetchange (P<0.05 for both
thresholds of 3 and 4 seconds). No significant association was detected when using
thresholds of 5 and 6 seconds. These findings may suggest that MTT thresholds below 4
seconds delineate both reversibly- and irreversibly-injured tissue, whereas MTT thresholds
above 5 seconds delineates only irreversibly-injured tissue. Thus, applying the more strict
thresholds (MTT greater than 5 seconds), reperfusion does not correlate well with clinical
improvement because regions with moderate perfusion deficit were excluded.
Discussion
The current voxel-by-voxel analysis of serial images focuses on tissue perfusion alterations
after tPA treatment within six hours after stroke onset. We have observed substantial spatial
and temporal heterogeneity of tissue perfusion in 15 tPA-treated patients. We demonstrated
that tissue outcome depends on the evolution of tissue perfusion in the hyper-acute phase of
ischemic stroke, with non-reperfused regions showing the highest infarction rate. Moreover,
we have found that many stroke patients develop regions of new hypoperfusion, or “delayed
hypoperfusion”; these regions increase infarct probability compared to normally perfused
tissue. Finally, NIHSS improvement was significantly associated with overall change in
perfusion status (%Vnetchange).
New Hypoperfusion
Regardless of the MTT threshold chosen, we observed the phenomenon of delayed or new
hypoperfusion: normally-perfused brain tissue at tp1 which becomes hypoperfused at tp2
(Table 1). All regions of new hypoperfusion fell within or were contiguous with the same
arterial territory that was initially affected. No distinct regions to suggest emboli or recurrent
strokes as the cause of new hypoperfusion were identified. Potential mechanisms that may
result in new hypoperfusion include disorders of the macro-circulation such as failure of
collaterals22, clot progression23, and recanalization followed by re-occlusion24. In addition,
disorders of the micro-vasculature may also be implicated. For example, after severe
ischemia, injured edematous capillary endothelial cells may lead to microvascular occlusion
accompanied by fibrin, platelet, and leukocyte plugging. Thus, even with recanalization,
distal vessels may not reperfuse, termed “no reflow” 25–28. This pro-coagulant and
inflammatory process may also lead to new areas of hypoperfusion. In addition,
microemboli of atherosclerotic debris may be released into the microcirculation causing
further distal embolization following thrombolysis29. Finally, peri-infarct depolarizations
(PID) may also contribute to new hypoperfusion. PIDs are waves of spreading depression
adjacent to ischemic tissue which result in progressive decreases in blood flow and infarct
growth. This novel phenomenon has been studied in animal models 30, 31 and has been
reported in human subjects during early stroke 32.
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Association between perfusion alterations and baseline clinical variables and outcomes
We found that delay to tPA treatment was independently associated with new
hypoperfusion, suggesting that earlier tPA treatment may limit its development. This finding
along with the results that new hypoperfusion increases the risk of tissue infarction have
clinical relevance as it has been demonstrated that late tPA treatment leads to a lower chance
of favorable outcome after stroke4, 5. We found that the initial hypoperfused volume
correlated positively with the volume of new hypoperfusion and negatively with relative
volume of reperfusion. Furthermore, we found that the non-reperfused regions have
significantly higher tp1 MTT values than the reperfused regions. These findings may
suggest that larger regions and more severe early ischemia are less likely to reperfuse,
resulting in a lower probability of tissue salvage. This is consistent with previous clinical
studies that have demonstrated that baseline clinical stroke severity, baseline hypoperfusion
severity, and large vessel occlusion are the strongest predictors of stroke evolution and early
neurological deterioration 33, 34.
For MTT thresholds ≤ 4 seconds, NIHSS reduction as a function of time was associated
with relative volume of improved perfusion but not with absolute volume. In this study, the
clinical improvement over time is a relative measure for a specific patient and it correlated
with how much of the initial ischemic volume improved proportionally (relative
improvement). We also expect that the location of the initial lesion may play an important
role in affecting the NIHSS change. A larger patient population may allow such
investigation in the future. Furthermore, we did not find an association between NIHSS
change and reperfusion for MTT thresholds of ≥ 5 seconds. This data may corroborate prior
studies which have found similar perfusion thresholds for distinguishing between
functionally-impaired, reversibly-injured tissue and structurally-impaired irreversibly-
injured tissue35, 36.
Our study has several limitations. Due to the small sample size in our study, the multiple
associations between perfusion alterations and baseline clinical variables tested (Figure 3)
may not have optimal statistical power. Given the limited number of patients in this study,
three associations (Figure 3c,d,f) with a P<0.05 should be considered as marginally
significant, while the other two associations (Figure 3b and e) with a P<0.01 showed
stronger correlations. Future study with a larger sample size is needed for further
investigation. In addition, our study population did not include untreated patients (only
patients treated with IV tPA). Therefore, we cannot be certain of how tPA may affect the
development of delayed hypoperfusion given the lack of a control group. Moreover, we
were unable to assess how tissue perfusion alterations affect clinical outcomes in our tPA-
treated group relative to patients who do not receive tPA. Our study included moderate to
large strokes with mean NIHSS of 14 and thus our results may not apply to patients with
smaller strokes. Limited tissue reperfusion may be attributed to the short time interval
between tPA administration and tp2. However, the majority of reperfusion after tPA is
thought to occur within two hours in some studies 24, 37, 38. Moreover, given the known
narrow therapeutic time-window, this analysis of early reperfusion is likely to be more
clinically meaningful. Finally, image co-registration was performed to align images across
all timepoints and imperfect alignment could inaccurately result in the appearance of new
hypoperfusion. In order to prevent this, we manually checked multiple structural landmarks
for each sequence within every timepoint for every patient and found misalignment less than
three voxels in any direction. In addition, isolated regions less than 1 ml were removed from
the analysis to prevent inclusion of regions of misregistration or noise-induced variations.
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We observed spatial heterogeneity of tissue perfusion in 15 tPA-treated patients with
dynamic perfusion between tp1 and tp2. Reperfusion, non-reperfusion, normal perfusion,
and new hypoperfusion were concurrently observed. Both non-reperfused and new
hypoperfused tissue adversely influenced tissue infarction risk. Our results suggest that
delay to tPA treatment and a large initial perfusion lesion may increase the risk of
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Scatter plots of absolute (ml) and relative volumes (%) of reperfusion, new hypoperfusion,
and net change in perfusion from all patients using MTT thresholds of 3 sec (a and b), 4 sec
(c and d), 5 sec (e and f), and 6 sec (g and h).
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Representative MTT at tp1 (a. e) and tp2 (b, f) from two patients (upper and lower panels).
This example used a MTT prolongation threshold of 4 sec. The hypoperfused region at tp1
and tp2 are in yellow (a,b,e,f). Reperfused (in green) and new hypoperfusion (in red) regions
are overlaid onto the tp3 FLAIR maps for both patients (c, g). 3D–rendered reperfused (in
green) and new hypoperfused (in red) regions are shown in d and h.
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A MTT prolongation threshold of 4 sec was used. (a) 3D scatter plot of Vreperf vs. OTT and
Vhypo_tp1 (diamonds). No statistically significant correlation was found between Vreperf and
any independent variables; (b) Scatter plot of %Vreperf vs. Vhypo_tp1 (diamonds) and their
statistically significant association (line, %Vreperf =−0.308* Vhypo_tp1 +48.51, r=−0.67,
P<0.01); (c) 3D scatter plot of Vnewhypo vs. both OTT and V hypo_tp1 and their statistically
significant association (linear plane, Vnewhypo =0.109*OTT+0.081* Vhypo_tp1 −11.71,
r=0.76, p<0.05). Color bar represents the value of Vnewhypo. (d) Scatter plot of %Vnewhypo
vs. OTT and their significant linear association (%Vnewhypo =0.144*OTT−9.26, r=0.57,
p<0.05); (e) Scatter plot of Vnetchange vs. OTT and their significant linear associations
(Vnetchange =−0.261*OTT+35.19, r=−0.59, p<0.01); (f) 3D scatter plot of %Vnetchange vs.
both OTT and Vhypo_tp1 and their statistically significant association (linear plane,
%Vnetchange =−0.329*OTT-0.349*Vhypo_tp1+80.16, r=−0.82, p<0.05). Color bar represents
the value of %Vnetchange. For a better visualization, filled diamonds represent the points
above the plane and open diamonds represent the points under the plane in (c) and (f). Only
statistically significant associations derived by the linear regression model were represented
by lines or planes.
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Table 1




Normal Perfusion Normal Normal
New Hypoperfusion Normal Hypoperfused
Normal: MTT prolongation < chosen MTT threshold
Hypoperfused: MTT prolongation ≥ a given MTT threshold

















Age, year (mean±SD) 61±15
Women, n (%) 5 (33%)
Stroke Syndrome R MCA: 8, L MCA:7
NIHSS
    Admission 14±6
    tp1 14±6
    tp2 12±7
    tp3 7±7
Findings on Admission
    Systolic blood pressure, mmHg 164±24
    Diastolic blood pressure, mmHg 82±12
    Blood glucose level, mg/dl 143±56
Time from Symptom Onset, hour
    Admission 0.9±0.6
    Treatment (OTT) 1.8±0.5
    tp1 2.7±0.7
    tp2 6.4±0.5
MCA=middle cerebral artery, L=left, R=right.













An et al. Page 16
Table 3
Tissue perfusion volumes, MTT prolongation, and risk of infarction for each of four MTT prolongation
thresholds (3–6 seconds)
MTT prolongation thresholds
3 sec 4 sec 5 sec 6 sec
Absolute volume (ml)
    Vhypo_tp1 70.8±49.1 60.6±45.9 52.8±42.3 46.4±36.7
    Vreperf 12.2±9.5 12±12.1 11.5±13.6 10.7±13.0
    Vnewhypo 5.6±7.4 4.9±6.8 4.7±6.6 4.5±6.7
    Vnetchange 6.6±11.6 7.1±13.6 6.8±15.1 6.2±15.2
MTT prolongation values at tp1 (sec) for initially hypoperfused Tissue
    Reperfusion 5.8±1.6 6.9±1.6 8.2±1.4 9.5±1.4
    Non-reperfusion 10±2.8 * 11.3±2.6 * 12.0±2.7 * 13.1±2.3 *
MTT prolongation values at tp1 (sec) for initially normal perfused tissue
    Normal Perfusion 0.5±0.5 0.8±0.5 1.1±0.5 1.3±0.5
    New-hypoperfusion 1.5±0.5 ¶ 2.3±0.6 ¶ 2.0±1.9 ¶ 3.2±1.3 ¶
Risk of Infarction for initially hypoperfused tissue
    Reperfusion 9.0±9.7 15.1±12.5 23.6±20.0 30.2±26.2
    Non-reperfusion 40.4±30.3 * 58.0±30.0 * 64.3±32.6 * 68.2±32.3 *
Risk of Infarction for initially normal perfused tissue
    Normal Perfusion 3.4±3.5 4.2±4.2 4.8±4.4 4.2±4.0
    New Hypoperfusion 19.0±23.3 ¶ 25.4±29.4 ¶ 37.2±36.7 ¶ 33.0±31.2 ¶
*
p<0.05, compared to the reperfused regions
¶
p<0.05 compared to the new hypoperfused regions
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